A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Trial Profile

A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Citarinostat (Primary) ; Ipilimumab; Nivolumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Acetylon Pharmaceuticals; Celgene Corporation
  • Most Recent Events

    • 22 Aug 2017 Status changed from recruiting to completed.
    • 14 Oct 2016 Status changed from planning to recruiting.
    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top